Analyse ADC heterogeneity and stability with NanoSight Pro. Detect aggregation early and optimise conjugation with particle-level insight.
Antibody-drug conjugates (ADCs) are among the most sophisticated and rapidly advancing classes of targeted therapeutics. By combining the specificity of monoclonal antibodies with highly potent cytotoxic payloads, ADCs enable precise delivery of treatment to diseased cells while minimising systemic exposure.
This therapeutic precision introduces a new level of molecular and formulation complexity. ADCs are inherently heterogeneous, with variability arising from conjugation processes, linker chemistry, and payload distribution. Maintaining control over this complexity is essential to ensure consistent efficacy, safety, and manufacturability.
At the nanoscale, even subtle changes in particle size, structure, or interaction can significantly influence ADC performance. Small shifts in stability or aggregation behaviour can alter pharmacokinetics, impact bioavailability, and increase immunogenicity risk. These effects are often not apparent until later stages of development.
The analytical challenge lies in detecting and understanding these changes early. Conventional techniques often rely on averaged measurements, which can obscure critical sub-populations and emerging instabilities. As a result, key risks may remain hidden until they become costly development issues.
With NanoSight Pro you can:
✔ Detect early-stage aggregation and sub-visible particle formation
✔ Gain particle-level insight into heterogeneous ADC populations
✔ Generate reproducible, decision-ready data to accelerate development
NanoSight Pro sets the benchmark for ADC analysis by delivering best-in-class nanoparticle tracking analysis with true particle-level resolution. It enables researchers to move beyond averaged measurements and directly observe the nanoscale behaviours that define stability and performance.
In a field where complexity drives risk, NanoSight Pro provides the clarity and confidence needed to control heterogeneity and accelerate successful therapeutic development.
Works with OmniTrust: Malvern Panalytical's compliance solution for the regulated environment
Antibody-drug conjugate development is defined by complexity at the molecular and nanoscale level, where small variations in structure, conjugation, and formulation can have a direct impact on stability, efficacy, and safety. While these systems are engineered for precision, they are inherently heterogeneous, and even subtle shifts in particle behaviour can introduce significant risk.
Many of these risks are not immediately visible using conventional analytical approaches, making early detection both challenging and essential. To successfully develop robust and reproducible ADCs, it is critical to identify and understand the underlying factors that drive variability and instability across particle populations.
These risks are difficult to detect because they originate at the nanoscale, where small changes can have disproportionate effects. Conventional analytical techniques often mask this complexity by reporting averaged values, making it challenging to identify low-abundance aggregates or distinct sub-populations. Without direct particle-level analysis, critical formulation behaviours can remain hidden until later stages of development.
NanoSight Pro addresses these challenges by enabling direct, particle-by-particle analysis through nanoparticle tracking analysis. By measuring particle size and concentration while visualising particles in real time, it reveals subtle variations and emerging instabilities that other techniques overlook.
NanoSight Pro combines sensitivity, resolution, and real-time visualisation to expose hidden risks early in development. This empowers teams to proactively manage heterogeneity, strengthen formulation strategies, and ensure more consistent and reliable ADC performance.
ADC development often fails late because subtle nanoscale changes accumulate over time and only become apparent during scale-up, storage, or real-world use. Variations in conjugation, stability, or particle interactions can lead to aggregation, reduced efficacy, or increased safety risks that were not detected earlier.
These issues frequently emerge when formulations are exposed to stress conditions or when manufacturing processes introduce variability. At this stage, addressing the root cause becomes significantly more complex and costly.
NanoSight Pro addresses this challenge through nanoparticle tracking analysis, enabling direct visualisation and measurement of individual particles in solution. By providing early detection of aggregation and heterogeneity, NanoSight Pro supports more informed decision-making and helps mitigate risk before it impacts development timelines.
With its ability to deliver high-resolution, early-stage insight, NanoSight Pro sets the standard for proactive risk management in ADC development. By identifying critical changes before they escalate, it helps reduce late-stage failure and enables more efficient, predictable development pathways.
ADC formulations are particularly susceptible to aggregation due to increased hydrophobicity and structural complexity. Detecting these changes early is critical to maintaining stability and ensuring consistent performance.
NanoSight Pro enables direct observation of individual particles, allowing researchers to identify low levels of aggregation and emerging sub-populations that would otherwise go unnoticed.
With NanoSight Pro, you can:
✔ Detect sub-visible aggregates before they impact development
✔ Monitor changes in particle size and concentration under stress conditions
✔ Identify early indicators of instability across formulations
NanoSight Pro redefines sensitivity in ADC analysis. As a best-in-class platform, it enables early detection of aggregation and instability at the nanoscale, supporting stronger formulations and more reliable therapeutic outcomes.
Achieving the optimal balance between efficacy and stability in ADCs requires precise control over conjugation and formulation parameters. Variability in drug loading and linker chemistry can significantly affect particle behaviour.
By providing size-resolved concentration data, NanoSight Pro enables a deeper understanding of how formulation changes influence particle populations and stability.
With NanoSight Pro, you can:
✔ Quantify particle concentration across heterogeneous size distributions
✔ Evaluate the impact of conjugation strategies on stability
✔ Optimise formulations based on real, particle-level data
By delivering precise, reproducible measurement at the particle level, NanoSight Pro sets a new standard for formulation optimisation. Its best-in-class capabilities enable greater control over conjugation strategies and more confident development decisions.
This supports the development of robust, stable monoclonal antibody formulations.
ADC systems are inherently heterogeneous, and understanding this complexity is essential for ensuring reproducibility and performance. Traditional methods often fail to resolve mixed populations with overlapping size ranges.
NanoSight Pro tracks individual particles in real time, revealing how different populations behave within the same sample and under varying conditions.
With NanoSight Pro, you can:
✔ Distinguish between multiple particle populations within a single formulation
✔ Observe real-time particle behaviour and interactions in solution
✔ Build a complete picture of ADC heterogeneity and stability
NanoSight Pro transforms how researchers understand complex ADC systems. By fully resolving heterogeneity and particle dynamics, it provides deeper insight that supports improved product quality and consistency.
NanoSight Pro delivers the analytical clarity required to navigate the complexity of ADC development. By moving beyond ensemble measurements, it provides direct insight into particle populations, enabling scientists to detect risks earlier and optimise formulations with greater precision.
This capability translates into stronger analytical control, improved reproducibility, and more efficient development pathways. For teams working at the forefront of targeted therapeutics, NanoSight Pro provides the confidence needed to make critical decisions based on robust, particle-level data.
With NanoSight Pro you can:
✔ Nanoparticle tracking analysis for direct particle visualisation
✔ Measurement of particle size and concentration in a single experiment
✔ Detection of low-abundance aggregates and sub-populations
✔ Resolution of heterogeneous particle distributions
✔ Real-time monitoring of particle behaviour under stress conditions
✔ Improved understanding of formulation stability and performance
✔ Early identification of development risks
✔ Enhanced reproducibility and batch consistency
✔ Stronger analytical support for regulatory submissions
✔ Accelerated development timelines through better decision-making
NanoSight Pro is the definitive solution for ADC characterisation. Combining precision, sensitivity, and depth of insight, it sets the industry standard for nanoparticle analysis in complex biologics. By revealing nanoscale changes that other techniques miss, it enables earlier decisions, reduces development risk, and supports more consistent, high-quality therapeutic outcomes.
Analyse ADC heterogeneity and stability with NanoSight Pro. Detect aggregation early and optimise conjugation with particle-level insight.
Characterise extracellular vesicles in cell therapy. Gain nanoscale insight into cell health, potency, and consistency with NanoSight Pro.
Analyse extracellular vesicles with precision using NanoSight Pro. Detect heterogeneity, quantify particles, and de-risk exosome development. Gain reproducible insight into vesicle behaviour in solution.
Characterise viral vectors with precision using NanoSight Pro. Measure size, concentration, and aggregation to support gene therapy development.
Characterize lipid nanoparticles with precision using NanoSight Pro to optimise delivery, stability, and performance in biopharma development.
Detect protein aggregation early with NanoSight Pro. Gain particle-level insight to improve stability, reduce risk, and accelerate biologics development.
Characterise nanomedicine particles with precision using NanoSight Pro. Improve stability, targeting, and development outcomes.
Discover how NanoSight Pro supports Quality Control and Quality Assurance by delivering reliable, reproducible data for regulatory compliant biologics and pharmaceutical development and manufacturing.
Gain reproducible insight into particle and molecular behaviour in vaccine systems. Detect instability, optimise formulations and accelerate vaccine development with Zetasizer.